SLS009 (tambiciclib)

About SELLAS Life Sciences

SELLAS Life Sciences is a clinical-stage biotech focused on developing transformative cancer therapies, with a mission centered on high-unmet-need oncology indications. Its strategy leverages two core platforms: a WT1-targeting peptide vaccine (GPS) and a highly selective CDK9 inhibitor (SLS009), both supported by strong clinical data and strategic partnerships. The company is approaching a pivotal inflection point with the final analysis of its Phase 3 REGAL trial in AML expected in 2026, backed by a strengthened balance sheet from recent warrant exercises.

About SELLAS Life Sciences

SELLAS Life Sciences is a clinical-stage biotech focused on developing transformative cancer therapies, with a mission centered on high-unmet-need oncology indications. Its strategy leverages two core platforms: a WT1-targeting peptide vaccine (GPS) and a highly selective CDK9 inhibitor (SLS009), both supported by strong clinical data and strategic partnerships. The company is approaching a pivotal inflection point with the final analysis of its Phase 3 REGAL trial in AML expected in 2026, backed by a strengthened balance sheet from recent warrant exercises.

About SELLAS Life Sciences

SELLAS Life Sciences is a clinical-stage biotech focused on developing transformative cancer therapies, with a mission centered on high-unmet-need oncology indications. Its strategy leverages two core platforms: a WT1-targeting peptide vaccine (GPS) and a highly selective CDK9 inhibitor (SLS009), both supported by strong clinical data and strategic partnerships. The company is approaching a pivotal inflection point with the final analysis of its Phase 3 REGAL trial in AML expected in 2026, backed by a strengthened balance sheet from recent warrant exercises.

Therapeutic Areas

Other Relapsed/Refractory AML Drugs